Medicine for treating osteoarthritis

Abstract

The invention discloses a medicine which cures osteoarthritis and is a compound which is formed by combining (S)-ibuprofen and dextrosamine or the medicine salt thereof according to 1:3 of mass ratio. The (S)-ibuprofen and the dextrosamine are prepared into compound preparation. The characteristics of rapid drug effects and strong abirritation of the (S)-ibuprofen can be used for rapidly relieving symptoms on the one hand; on the other hand, the dextrosamine can defer cartilage degeneration process, repairs cartilage pathological changes, and prevents, even reverses the disease process. Meanwhile, the (S)-ibuprofen and the dextrosamine are prepared into the compound preparation, which can reduce the dose of single medicine and further reduce the toxic side effects. The compound preparation prepared by the (S)-ibuprofen and the dextrosamine of the invention becomes a new medicine which can cure the osteoarthritis.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to a new drug for treating osteoarthritis. Background technique: [0002] 1. The incidence of osteoarthritis [0003] Osteoarthritis (OA), also known as osteoarthritis, degenerative joint disease, senile arthritis, proliferative arthritis, hypertrophic arthritis, is divided into primary arthritis and secondary arthritis. Osteoarthritis is characterized by pain, inflammation, stiffness, swelling, deformity, and dysfunction in the joints of the hands, wrists, ankles, knees, hips, shoulders, and spine. The articular cartilage of the human body inevitably degenerates and wears out with age. The degeneration of cartilage begins in the late 20s. Most people over the age of 50 can show the performance of osteoarthritis on X-rays. 65 Almost all the elderly over the age of 10 suffer from obvious osteoarthritis, so osteoarthritis is a common and frequently-occurring disease in middle-aged and elder...

AI Technical Summary

Problems solved by technology

At present, the compound preparation of non-steroidal anti-inflammatory drugs and glucosamine enteric-coated tablets of NSAIDs and glucosamine on the domestic market, due to the serious adverse reactions of indomethacin in the prescription, the sales ranking of the drug has declined; and animal experiments have shown that The combination of glucosamine and some analgesic drugs such as acetaminophen, diclofenac, indomethacin, piroxicam, naproxen, etc. only has additive effect, subadditive effect or even no effect (RONALD J.TALLARIDA, ALAND COWAN, and ROBERT B. RAFFA; Antinociceptive Synergy, Additivity, and Subadditivity with Combinations of OralGlucosamine Plus Nonopioid Analgesics in Mice; the Journal of Pharmacology and Experimental Therapeutics, Vol.307, No.2)

Images